Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Department of Population and Clinical Science, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Ann Surg Oncol. 2022 Dec;29(13):8413-8420. doi: 10.1245/s10434-022-12390-7. Epub 2022 Aug 26.
Veteran populations have five times the incidence of hepatocellular carcinoma (HCC) compared with the general population. The incidence of HCC has increased in the Veteran's Affairs Health System (VAHS), primarily due to the increased prevalence of cirrhosis. This study aimed to characterize differences in treatment patterns and overall survival rates across the five VAHS geographic regions.
Using the VA Corporate Data Warehouse, the authors built a comprehensive national dataset of Veteran patients with HCC diagnosed between 2001 and 2015 to compare patients across VAHS regions. A multivariable Cox proportional hazards model was used to identify factors associated with 5-year all-cause mortality. Kaplan-Meier curves were used to visualize the patient survival function, and the log-rank test was applied to test statistical significance.
This retrospective study analyzed 13,434 patients. The West region had the highest rate of overall treatment receipt (63.6%), and the Southwest had the lowest rate (52.9%). After adjustment for demographic, clinicopathologic, treatment, and hospital factors, treatment in a non-West region continued to be significantly associated with a 10% to 13% increased risk of 5-year mortality (Midwest: hazard ratio [HR], 1.11; 95% confidence interval [CI], 1.03-1.17; Northeast: HR, 1.10; 95% CI, 1.03-1.17; Southeast: HR, 1.13; 95% CI, 1.06-1.21; Southwest: HR, 1.11; 95% CI, 1.03-1.19) (p < 0.01).
Treatment patterns and overall survival rates of HCC patients differ significantly across VAHS geographic regions. Targeted interventions to increase the rate of treatment in the non-West regions are needed to improve survival of HCC Veterans and provide uniformly high-quality care across VAHS facilities.
与普通人群相比,退伍军人的肝细胞癌(HCC)发病率是其五倍。由于肝硬化的发病率增加,退伍军人事务部医疗保健系统(VAHS)中的 HCC 发病率有所上升。本研究旨在描述 VAHS 五个地理区域之间治疗模式和总生存率的差异。
作者利用 VA 公司数据仓库,构建了一个包含 2001 年至 2015 年间确诊 HCC 的退伍军人患者的全国性综合数据集,以比较 VAHS 地区的患者。采用多变量 Cox 比例风险模型来确定与 5 年全因死亡率相关的因素。Kaplan-Meier 曲线用于可视化患者的生存函数,对数秩检验用于检验统计学意义。
这项回顾性研究共分析了 13434 名患者。西部地区的总体治疗率最高(63.6%),而西南部地区的治疗率最低(52.9%)。在调整人口统计学、临床病理、治疗和医院因素后,在非西部地区进行治疗仍然与 5 年死亡率增加 10%至 13%显著相关(中西部:风险比 [HR],1.11;95%置信区间 [CI],1.03-1.17;东北部:HR,1.10;95% CI,1.03-1.17;东南部:HR,1.13;95% CI,1.06-1.21;西南部:HR,1.11;95% CI,1.03-1.19)(p < 0.01)。
VAHS 地理区域之间 HCC 患者的治疗模式和总体生存率存在显著差异。需要采取有针对性的干预措施来提高非西部地区的治疗率,以提高 HCC 退伍军人的生存率,并在 VAHS 设施中提供统一的高质量护理。